Nephrology Division, Assaf-Harofeh (Shamir) Medical Center, Be'er Ya'akov, Israel.
Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Front Immunol. 2020 Jul 21;11:1369. doi: 10.3389/fimmu.2020.01369. eCollection 2020.
There is growing evidence concerning the potential use of mesenchymal stromal cells (MSCs) for different tissue injuries. Initially, the intended physiological use of MSCs was due to their ability to differentiate and replace damaged cells. However, MSCs have multiple effects, including being able to significantly modulate immunological responses. MSCs are currently being tested for neurodegenerative diseases, graft vs. host disease, kidney injury, and other chronic unremitting tissue damage. Using MSCs in acute tissue damage is only now being studied. Acute kidney injury (AKI) is a common cause of morbidity and mortality. After the primary insult, overactivation of the immune system culminates in additional secondary potentially permanent kidney damage. MSCs have the potential to ameliorate the secondary damage, and recent studies have shed important light on their mechanisms of action. This article summarizes the basics of MSCs therapy, the newly discovered mechanisms of action, and their potential application in the setting of AKI.
越来越多的证据表明间充质基质细胞(MSCs)可能用于治疗不同的组织损伤。最初,MSCs 的预期生理用途是由于其能够分化和替代受损细胞。然而,MSCs 具有多种作用,包括能够显著调节免疫反应。目前正在对 MSCs 进行神经退行性疾病、移植物抗宿主病、肾损伤和其他慢性持续组织损伤的测试。在急性组织损伤中使用 MSCs 目前才开始研究。急性肾损伤(AKI)是发病率和死亡率的常见原因。在最初的损伤后,免疫系统的过度激活会导致额外的继发性潜在永久性肾损伤。MSCs 有可能减轻继发性损伤,最近的研究为其作用机制提供了重要的启示。本文总结了 MSCs 治疗的基础知识、新发现的作用机制以及它们在 AKI 中的潜在应用。